We are live on !
Find out more
Logos Global Management Portfolio holdings
AUM
$2.32B
Turnover
52.75%
1-Year Est. Return
536.01%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$320M
(+16%)
Cap. Flow
-$21M
Cap. Flow % of AUM
Cap. Flow %
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
48.35%
Holding
91
New
25
Increased
18
Reduced
19
Closed
23
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$95.5M |
| 2 |
Vera Therapeutics
VERA
|
+$82M |
| 3 |
Celldex Therapeutics
CLDX
|
+$53.3M |
| 4 |
Abivax
ABVX
|
+$39.5M |
| 5 |
Belite Bio
BLTE
|
+$38.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$190M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$84.4M |
| 3 |
Terns Pharmaceuticals
TERN
|
+$79.1M |
| 4 |
Cytokinetics
CYTK
|
+$57.7M |
| 5 |
United Therapeutics
UTHR
|
+$47.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Editas Medicine
EDIT
$369M
| $7.2M | 0.31% |
+2,222,000
| New | +$6.49M |
2026 Q2
0 quarters
|
|
52
Relay Therapeutics
RLAY
$3.97B
| $6.55M | 0.28% |
350,000
-400,000
| -53% | -$5.81M |
2026 Q1
1 quarter
|
|
53
Acadia Pharmaceuticals
ACAD
$3.4B
| $6.32M | 0.27% |
250,000
-500,000
| -67% | -$11M |
2025 Q4
2 quarters
|
|
54
Amylyx Pharmaceuticals
AMLX
$3.4B
| $6.29M | 0.27% |
350,000
-350,000
| -50% | -$5.41M |
2025 Q3
3 quarters
|
|
|
HELP
55
Helus Pharma Inc. Common Stock
HELP
$757M
| $4.96M | 0.21% |
+750,000
| New | +$3.75M |
2026 Q2
0 quarters
|
|
56
OnKure Therapeutics
OKUR
$100M
| $4.4M | 0.19% |
+963,855
| New | +$4.14M |
2026 Q2
0 quarters
|
|
57
Tenax Therapeutics
TENX
$61.4M
| $4.36M | 0.19% |
300,000
-325,000
| -52% | -$4.15M |
2026 Q1
1 quarter
|
|
58
Definium Therapeutics
DFTX
$4.79B
| $3.76M | 0.16% |
+80,000
| New | +$1.98M |
2026 Q2
0 quarters
|
|
59
Unicycive Therapeutics
UNCY
$100M
| $2.22M | 0.1% |
473,563
| – | – |
2024 Q1
9 quarters
|
|
60
Palatin Technologies
PTN
$8.58M
| $1.4M | 0.06% |
130,000
-10,000
| -7% | -$165K |
2025 Q4
2 quarters
|
|
61
uniQure
QURE
$1.5B
| $1.38M | 0.06% |
+30,000
| New | +$785K |
2026 Q2
0 quarters
|
|
62
JATT II Acquisition Corp
JATT
$80.3M
| $1.14M | 0.05% |
+100,000
| New | +$1.06M |
2026 Q2
0 quarters
|
|
63
Research Alliance Corp III
RACC
$91.7M
| $1.07M | 0.05% |
+100,000
| New | +$1.04M |
2026 Q2
0 quarters
|
|
64
Aclaris Therapeutics
ACRS
$558M
| $1.06M | 0.05% |
200,000
-300,000
| -60% | -$1.34M |
2024 Q4
6 quarters
|
|
|
LGVN
65
Longeveron
LGVN
$5.1M
| $905K | 0.04% |
+128,700
| New | +$1.11M |
2026 Q2
0 quarters
|
|
66
Fractyl Health
GUTS
$14.2M
| $794K | 0.03% |
83,333
| – | – |
2025 Q3
3 quarters
|
|
67
Septerna Inc
SEPN
$1.93B
| $789K | 0.03% |
23,548
| – | – |
2024 Q4
6 quarters
|
|
68
Amanat Acquisition Corp
AMAN
$98.7M
| $508K | 0.02% |
+50,000
| New | +$505K |
2026 Q2
0 quarters
|
|
69
Alkermes
ALKS
$7.46B
| – | – |
-350,000
| Closed | -$12.4M | – |
|
70
CALL
Avalo Therapeutics
AVTX
$363M
| – | – |
-1,000,000
| Closed | -$14.9M | – |
|
71
Biogen
BIIB
$37.3B
| – | – |
-200,000
| Closed | -$36.7M | – |
|
72
Compass Therapeutics
CMPX
$135M
| – | – |
-3,150,000
| Closed | -$16.7M | – |
|
|
CNTA
73
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-2,125,000
| Closed | -$84.4M | – |
|
74
Corvus Pharmaceuticals
CRVS
$879M
| – | – |
-450,000
| Closed | -$6.58M | – |
|
|
75
Cytokinetics
CYTK
$8.44B
| – | – |
-875,000
| Closed | -$57.7M | – |
|
Similar funds
CWM
Logos Global Management's Q2 2026 Portfolio in Review
As of Q2 2026, Logos Global Management held 91 positions worth $2.32B, up 16% from $2B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Logos Global Management's Q2 2026 filing shows 25 new, 18 increased, 19 reduced and 23 closed positions. Its largest new stake was BioNTech: 1,015,000 shares worth $94.4M. The largest sale was Revolution Medicines, an estimated $190M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Financials.
- Logos Global Management's largest Q2 2026 buy was BioNTech: 1,015,000 shares worth $94.4M.
- Logos Global Management added most to Celldex Therapeutics in Q2 2026, an estimated $53.3M increase.
- Logos Global Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $190M.
- Logos Global Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $84.4M.
- Logos Global Management's ten largest holdings make up 48% of its $2.32B portfolio in Q2 2026.
- Logos Global Management opened 25 new positions and closed 23 in Q2 2026.
- Logos Global Management's portfolio value rose 16% quarter-over-quarter to $2.32B.
Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.